{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-061496","form_type":"8-K","ticker":"SYBX","cik":"0001527599","company_name":"SYNLOGIC, INC.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.374315+00:00","generated_at":"2026-06-08T06:39:18.173481+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Synlogic Q3 net loss narrows to $12.1M; cash runway extended into H1 2025","bullets":["Net loss of $12.1M ($2.57 per share) vs $17.9M ($3.73) in Q3 2022; revenue $0.4M from Roche collaboration.","Closed $21M underwritten public offering and earned $2.5M Roche milestone, extending cash runway into H1 2025.","Synpheny-3 pivotal trial in PKU on track: enrollment completion H2 2024, top-line data H1 2025.","FDA granted Fast Track Designation for labafenogene marselecobac (SYNB1934) for PKU.","Cash and investments $33.4M as of Sept 30, plus $19.6M net from October financing and $2.5M milestone."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-061496","json":"https://secwatch.observer/filing/0000950170-23-061496.json","markdown":"https://secwatch.observer/filing/0000950170-23-061496.md","text":"https://secwatch.observer/filing/0000950170-23-061496.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1527599/000095017023061496/0000950170-23-061496-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1527599/000095017023061496/sybx-20231109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T06:39:18.173481+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a7b97538c1253ec720a45f4e2327e4999aa12228","claim":"SYNLOGIC, INC. reported the quarter ended September 30, 2023 results: revenue $0.4 million, net income $12.1 million, or $2.57 per share, EPS $2.57 per share.","evidence_excerpt":"$19.6 million (net), and an additional $2.5 million earned from the Roche research collaboration announced in November. Revenue for the three months ended September 30, 2023 was $0.4 million compared to $0.7 million for the corresponding period in 2022. Revenue in both periods was primarily associated with the ongoing research collaboration with Roche for the","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1527599/000095017023061496/0000950170-23-061496-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Revenue","value":"$0.4 million"},{"label":"Net income","value":"$12.1 million, or $2.57 per share"},{"label":"EPS","value":"$2.57 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}